Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.

Artificial intelligence-based models have become a growing area of interest in clinical oncology. What do we need to know about them? Dr. Benjamin Kann, a physician at Dana Farber Cancer Institute, and Assistant Professor of radiation oncology at Harvard Medical School, meets with Dr. Jacob Sands to discuss the use of AI in oncology.

Dr. Brian T. Hill, a physician in the Department of Hematology and Medical Oncology at Cleveland Clinic, explores some of the most recent—and ongoing—impacts of the COVID-19 pandemic on treatment decision-making for patients with chronic lymphocytic leukemia.

Dr. Jacob Sands is joined by Dr. Elizabeth Brém, an Assistant Professor in the Division of Hematology/Oncology at the University of California Irvine School of Medicine to explore opportunities and challenges with fixed duration therapy for patients with chronic lymphocytic leukemia.

Dr. Jennifer Caudle is joined by Dr. Lindsey Roeker, a hematologist and medical oncologist at Memorial Sloan Kettering Cancer Center, to discuss evolving outcome measures and critical diagnostic biomarkers in patients with chronic lymphocytic leukemia.

Is frontline treatment for chronic lymphocytic leukemia evolving? Dr. Jacob Sands is joined by Dr. Bruce Cheson, a Scientific Advisor at the Lymphoma Research Foundation, to review the CLL treatment landscape and take a look at emerging data on long-term outcomes.

Dr. Jennifer Caudle is joined by Dr. Jennifer A. Woyach, a professor in the Division of Hematology at Ohio State University, to discuss tailoring treatment to unique populations for patients with chronic lymphocytic leukemia.

Did you know that the current 5-year survival rate for patients diagnosed with metastatic RCC is only 12% despite advances in molecular research over the past decade? Are you familiar with recent treatment guidelines and clinical trial data showcasing the benefits of treating poor- and intermediate-risk ccRCC patients with immuno-oncology/tyrosine kinase inhibitor combination therapy? This virtual tumor board features a multidisciplinary expert panel presenting a poor-risk patient case and discussing treatment strategies and evidence-based therapy selection to optimize patient outcomes. Faculty additionally cover the importance of incorporating the patient perspective and adverse event profiles into treatment decisions.

After viewing the activity, visit the Related tab for supplemental resources.

Non-clear cell renal cell carcinoma is one of the rare diseases with limited treatment data, creating many challenges for oncologists. But could recent updates radically change the landscape? To find out, Dr. Jacob Sands speaks with Dr. Brad McGregor, the Clinical Director for the Lank Center for Genitourinary Oncology at the Dana-Farber Cancer Institute in Boston, to discuss developments in the management of non-clear cell renal cell carcinoma.

CT scans have the potential to dramatically improve lung cancer outcomes, but are underserved communities receiving access to these types of screenings? Dr. Jacob Sands joins Dr. Derek Raghavan, President of Atrium Health Levine Cancer Institute in Charlotte, North Carolina, to discuss his research presented at the American Society of Clinical Oncology Annual Meeting.